Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #176633 on Innovation Pharmaceuticals Inc (IPIX)
georgejjl
03/28/17 8:50 PM
#176635 RE: F1ash #176633
“We have received excellent results, to date, in our Brilacidin IBD trial, both regarding objective scores and subjective assessments. The systemic absorption of Brilacidin has been minimal while still yielding compelling patient responses,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix. “We’re getting exactly what we need from a proof-of-concept study—clear and strong signals both as to the safety and the efficacy of Brilacidin in treating IBD. These results will help guide the continued development of Brilacidin, including planned foam and oral formulations, for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn’s Disease.”
TheHound
03/28/17 8:53 PM
#176636 RE: F1ash #176633